Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab and SLIT-HDM in Severe Atopic Dermatitis
NCT06509243Completed
- Sponsor
- Medical University of Silesia
- Start
- Feb 2023
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies, Allergy Immunotherapy
- Countries
- 1
01
Overview
Randomised, double-blind trial of dupilumab and House dust mite allergen extract in atopic dermatitis (AD) (4 arms), sponsored by Medical University of Silesia. Primary endpoints: Eczema Area and Severity Index at 12 months, Body Surface Area at 12 months and 1 more. Started Feb 2023; status: completed.
02
Drugs
dupilumabHouse dust mite allergen extract
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06509243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06509243.